Pluri Inc
NASDAQ:PLUR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Pluri Inc
Total Current Liabilities
Pluri Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pluri Inc
NASDAQ:PLUR
|
Total Current Liabilities
$32.3m
|
CAGR 3-Years
83%
|
CAGR 5-Years
26%
|
CAGR 10-Years
22%
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Total Current Liabilities
$47.4m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
14%
|
CAGR 10-Years
8%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Total Current Liabilities
$3m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
6%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Total Current Liabilities
$46.4m
|
CAGR 3-Years
25%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Total Current Liabilities
$1.6m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
M
|
Matricelf Ltd
TASE:MTLF
|
Total Current Liabilities
₪2.4m
|
CAGR 3-Years
19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pluri Inc
Glance View
Pluri Inc is a IL-based company operating in Biotechnology industry. Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The firm's products include PLX-PAD and PLX R18. The firm's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The firm's PLX products are administered using a standard needle and syringe. The firm's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.
See Also
What is Pluri Inc's Total Current Liabilities?
Total Current Liabilities
32.3m
USD
Based on the financial report for Dec 31, 2025, Pluri Inc's Total Current Liabilities amounts to 32.3m USD.
What is Pluri Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
22%
Over the last year, the Total Current Liabilities growth was 629%. The average annual Total Current Liabilities growth rates for Pluri Inc have been 83% over the past three years , 26% over the past five years , and 22% over the past ten years .
